… 23.5% of the first quarter revenues, remaining flat on a … Finally, our Healthcare and Pharma, and Other verticals remained flat … of revenues, in the first quarter of 2024. Non-GAAP gross profit was … ;investors with the passcode $Q1@2025. About Grid Dynamics …

… reported the following first quarter results for the … Aptar Reports First Quarter 2025 Results First Quarter 2025 Highlights ( … First Quarter Segment Sales Analysis (Change Over Prior Year)   Aptar Pharma … quarter, with royalty revenues helping drive adjusted …

… beyond." First Quarter 2025 Financial Highlights Total Revenues for the first quarter of 2025 … -reports-first-quarter-2025-results-and-reaffirms-full-year-guidance-302444297.html SOURCE BioMarin Pharmaceutical …

… TVTX) today reported its first quarter 2025 financial results and … ® (sparsentan) – IgAN First quarter 2025 FILSPARI U.S. net … expectations regarding Renalys Pharma’s registrational Phase 3 …     39,984   License and collaboration revenue   5,871       1,390 …

… safety, tolerability, and pharmacokinetics, and determine the … pipeline in 2025. First Quarter 2025 Business Highlights and … one investor meetings. First Quarter 2025 Financial Results …   2025       2024   Collaboration revenue $ —     $ 1,115   Operating …

… Pharmaceuticals, Inc. (NASDAQ: TARS), today announced financial results for the first quarter … the end of Q1 2025, the … About Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc. … fees and collaboration revenue   —       2,894   Total revenues   78,335 …

Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billion Organic net sales increased 10.1% Reported operating …

– NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting …

… our MRD business to profitability and advancing our … stakeholders.” Recent Highlights Revenue for the first quarter of 2025 was … tests delivered versus the first quarter of 2024. Received … million in MRD pharma regulatory milestone revenue. Raising full year …

Delivers Q1 revenue of $926.9 million, up 47.5% year over year, and grows Medicare Advantage (MA) membership by 31.7% to approximately 217,500 members Exceeds high-end of Q1 guidance on membership, revenue, adjusted gross profit and adjusted EBITDA Raises …